文献速递乳腺乳腺X线USMR

CHEK2与BRCA1及BRCA2基因突变携带者乳腺癌影像学特征比较

Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers.
PubMed 文献 · Eur J Radiol · 2021-11-26

该研究纳入同一医院诊治的191例BRCA1、BRCA2或CHEK2基因突变携带者的233个原发性乳腺癌病灶,比较钼靶、超声和MRI影像特征。CHEK2携带者钼靶可疑微钙化占54%,高于BRCA2的48%和BRCA1的33%(P=0.057);MRI 3型曲线在CHEK2占67%,BRCA1为36%、BRCA2为50%(P=0.056)。作者认为CHEK2与BRCA2携带者可疑微钙化较BRCA1更常见(但无显著差异),提示钼靶在CHEK2携带者随访中的重要性。

要点

  • CHEK2携带者钼靶可疑微钙化占54%,高于BRCA2的48%和BRCA1的33%(P=0.057)。
  • CHEK2携带者MRI肿块3型曲线占67%,BRCA1为36%、BRCA2为50%(P=0.056)。
  • CHEK2携带者超声病灶多表现为边界不清(86%)和不规则形(94.5%)。

核心结论

  • CHEK2与BRCA2携带者乳腺癌钼靶可疑微钙化较BRCA1更常见但无显著差异,提示钼靶在CHEK2携带者随访中的重要性。

研究设计与样本

  • 回顾性比较研究,纳入同一医院诊治的191例基因突变携带者的233个原发性乳腺癌病灶(BRCA1 78个、BRCA2 109个、CHEK2 46个),分析钼靶、超声和MRI特征。

关键影像表现/征象

  • CHEK2携带者钼靶表现以可疑微钙化为主(54%),高于肿块病变(35%)。
  • CHEK2携带者超声病灶多边界不清(86%)且形态不规则(94.5%)。
  • CHEK2携带者MRI肿块3型曲线占67%,BRCA1为36%、BRCA2为50%。

诊断标准与关键数值

  • 钼靶可疑微钙化比例:CHEK2 54% vs BRCA2 48% vs BRCA1 33%(P=0.057)。
  • 超声边界不清比例:CHEK2 86% vs BRCA2 77% vs BRCA1 71%(P=0.579)。
  • 超声形态不规则比例:CHEK2 94.5% vs BRCA2 80% vs BRCA1 72%(P=0.098)。
  • MRI 3型曲线比例:CHEK2 67% vs BRCA1 36% vs BRCA2 50%(P=0.056)。

临床应用与阅片要点

  • 对CHEK2携带者随访时,钼靶对可疑微钙化的检出可能重要(作者结论)。
  • CHEK2携带者超声多表现为边界不清、形态不规则,阅片时需注意。
  • CHEK2携带者MRI肿块强化曲线以3型多见,比例高于BRCA1和BRCA2。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: Breast cancer gene (BRCA) 1 and 2 mutations are frequently studied gene mutations (GM); the incidence of checkpoint kinase 2 (CHEK2) is increasing. We describe the imaging features of breast cancer (BC) in CHEK2 mutations, compared to BRCA 1 and 2 using mammography, ultrasound (US) and magnetic resonance imaging (MRI).

METHOD: Inclusion criteria were primary BC in GM carriers, treated in the same hospital. Age at diagnosis, histology, hormone receptor and human epidermal growth factor receptor 2 (HER2) status were retrieved. Mammography descriptors were mass, asymmetry and suspicious microcalcifications. The enhancement pattern (MRI), shape and border, architectural distortion, the presence of a hyperechoic rim and cystic complex structure (US) were documented. Analyses were performed using SAS software (version 9.4). Fishers' exact test was used to test associations between two categorical variables.

RESULTS: In 191 women, 233 malignant lesions were diagnosed (78 in BRCA1, 109 in BRCA2, 46 in CHEK2). In CHEK2 carriers, mammographically, suspicious microcalcifications (54%) were more prevalent (BRCA2 (48%) and BRCA1 carriers (33%)) (p-value = 0.057) compared to mass lesions (35%). On US, lesions were most frequently ill-defined (86%) (p = 0.579) and irregular (94.5%) (p = 0.098) compared to BRCA2 (77% and 80% resp.) and BRCA1 carriers (71% and 72% resp.). On MRI, mass lesions showed a type 3 curve in CHEK2 (67%) compared to BRCA1 (36%) and BRCA2 (50%) (p = 0.056).

CONCLUSIONS: Malignant radiological characteristics of breast cancer, more specifically suspicious microcalcifications, were more frequently seen in CHEK2 and BRCA2 compared to BRCA1 mutation carriers (without a significant difference) indicating the importance of mammography in follow-up of CHEK2 carriers.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Ghunaim, Laenen, De Keyzer, et al. Comparing breast cancer imaging characteristics of CHEK2 with BRCA1 and BRCA2 gene mutation carriers. Eur J Radiol. 2021. PMID: 34902667. doi:10.1016/j.ejrad.2021.110074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。